Trends & Strategies in the $4.3 Billion Soft Tissue Sarcoma Market, 2026-2031

Trends & Strategies in the $4.3 Billion Soft Tissue Sarcoma Market, 2026-2031 Dublin, Aug. 18, 2026 (GLOBE NEWSWIRE) -- The "Soft Tissue Sarcoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The global soft tissue sarcoma market is projected to increase from USD 4.03 billion in 2025 to USD 4.38 billion in 2026, reaching USD 6.67 billion by 2031. The market is forecast to record a CAGR of 8.75% from 2026 to 2031, supported by rising disease incidence, earlier referrals to specialist centers, expanding molecular diagnostics and the development of targeted therapies and immunotherapies.

The market report provides revenue forecasts by offering, sarcoma type, end user and geography. It assesses diagnosis and treatment services across liposarcoma, leiomyosarcoma, synovial sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor and other histologic subtypes. End-user coverage includes hospitals, cancer research centers, diagnostic laboratories, ambulatory surgical centers and other healthcare organizations.

Earlier Referral Strengthens Soft Tissue Sarcoma Diagnosis and Treatment

Increasing soft tissue sarcoma incidence and stronger surveillance are expanding patient access to specialist pathways. Cancer Research UK reported that incidence rates in England increased by 7% over the past decade, with demographic aging and improved surveillance contributing to the change. Earlier referrals are supporting more coordinated use of MRI, core needle biopsy, pathology review and molecular testing.

Clinical guidelines and multidisciplinary tumor boards are also standardizing referral and diagnostic procedures. Regional sarcoma centers across Germany, France and the United Kingdom are helping reduce delays between initial suspicion, specialist consultation and treatment planning. These developments are increasing procedure intensity per patient and supporting demand across imaging, biopsy, laboratory testing and precision oncology services.

Targeted Therapy and Immunotherapy Pipelines Accelerate Market Growth

The expansion of biomarker-selected treatments is reshaping the competitive outlook for the soft tissue sarcoma market. The FDA's accelerated approval of afamitresgene autoleucel in August 2024 for unresectable or metastatic synovial sarcoma established an important milestone for engineered T-cell receptor therapy in solid tumors. Full approval in June 2026 expanded the eligible population to patients aged 12 years and older, reinforcing the commercial potential of specialist-administered cellular therapies.

Investment is also increasing across PD-1 and PD-L1 programs, CDK4-directed therapies, antibody-drug conjugates and next-generation T-cell receptor platforms. As subtype-specific pipelines mature, competitive performance will increasingly depend on biomarker testing capacity, specialist referral networks and access to qualified treatment centers.

Market expansion remains constrained by fragmented patient populations. Soft tissue sarcoma includes more than 70 histologic subtypes, limiting trial recruitment and statistical power in rare indications. Sponsors are responding with basket trials, biomarker-selected cohorts and approval strategies based on response endpoints. However, recruitment bottlenecks may continue to slow product launches compared with larger oncology markets.

Segment Analysis

Treatment accounted for 68.31% of the soft tissue sarcoma market in 2025 and is projected to remain the fastest-growing offering segment, recording a CAGR of 9.38% through 2031. Surgery, systemic therapy, radiation therapy and combination regimens continue to anchor care pathways. Chemotherapy retains broad clinical use, while targeted treatments and immunotherapies are increasing revenue opportunities in biomarker-selected populations.

The diagnosis segment is becoming more strategically important as treatment eligibility increasingly requires biomarker confirmation. Comprehensive genomic profiling, fusion detection and MAGE-A4-associated testing are strengthening demand for pathology and molecular laboratory services. MRI remains central to diagnostic workups, while liquid biopsy and circulating tumor DNA applications are progressing in response monitoring and minimal residual disease assessment.

Regional Market Outlook

North America held 41.61% of the global soft tissue sarcoma market in 2025, making it the leading region by revenue. Its position is supported by extensive specialist center coverage, orphan drug development frameworks, advanced molecular testing and reimbursement systems capable of supporting premium oncology therapies. The United States accounts for most regional revenue due to its established referral networks, qualified treatment infrastructure and strong commercial adoption of new therapies.

Europe represents the second-largest regional market, supported by reference networks and concentrated expertise across Germany, France, Italy, Spain and the United Kingdom. These networks strengthen clinical trial participation, pathology review and access to multidisciplinary treatment planning.

Asia-Pacific is forecast to be the fastest-growing region, with a CAGR of 9.65% through 2031. Growth is being driven by expanding molecular diagnostics, rising oncology investment and regulatory initiatives for rare cancers. Japan's February 2025 approval of atezolizumab for unresectable alveolar soft part sarcoma marked a significant regional development. China offers substantial long-term potential, although molecular profiling and standardized post-operative management remain uneven outside major urban centers.

South Korea is benefiting from a strong diagnostics environment, while India is gaining importance through oncology research investment and broader clinical trial participation. South America and the Middle East and Africa remain developing markets, with access concentrated in major cities. Brazil and Argentina lead demand in South America, while GCC countries continue to invest in cancer center capacity.

Key Topics Covered

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Incidence of Soft Tissue Sarcoma and Earlier Referral to Specialty Centers

4.2.2 Expansion of Targeted Therapy and Immunotherapy Pipelines

4.2.3 Greater Use of MRI, Core Needle Biopsy, and Molecular Profiling in Diagnostic Workups

4.2.4 Liquid Biopsy and ctDNA Adoption for Response Monitoring and Minimal Residual Disease Detection

4.2.5 Biomarker-Linked Treatment Selection in Rare Sarcoma Subtypes

4.3 Market Restraints

4.3.1 Small Patient Pools and Trial Recruitment Bottlenecks Across Subtypes

4.3.2 High Cost of Multimodal Treatment and Advanced Diagnostics

4.3.3 Limited Pathology and Sarcoma-Center Access in Emerging Markets

4.4 Regulatory Landscape

4.5 Technological Outlook

4.6 Porter's Five Forces Analysis

4.6.1 Threat of New Entrants

4.6.2 Bargaining Power of Suppliers

4.6.3 Bargaining Power of Buyers

4.6.4 Threat of Substitutes

4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

5.1 By Offering

5.1.1 Diagnosis

5.1.1.1 Biopsy

5.1.1.2 Imaging

5.1.1.3 Molecular Diagnostics

5.1.1.4 Other Diagnostic Methods

5.1.2 Treatment

5.1.2.1 Surgery

5.1.2.2 Radiation Therapy

5.1.2.3 Chemotherapy

5.1.2.4 Targeted Therapy

5.1.2.5 Immunotherapy

5.1.2.6 Other Treatments

5.2 By Type of Sarcoma

5.2.1 Liposarcoma

5.2.2 Leiomyosarcoma

5.2.3 Synovial Sarcoma

5.2.4 Rhabdomyosarcoma

5.2.5 Malignant Peripheral Nerve Sheath Tumor (MPNST)

5.2.6 Other Types of Sarcoma

5.3 By End User

5.3.1 Hospitals

5.3.2 Cancer Research Centers

5.3.3 Diagnostic Laboratories

5.3.4 Ambulatory Surgical Centers

5.3.5 Other End Users

5.4 By Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

5.4.3.4 Australia

5.4.3.5 South Korea

5.4.3.6 Rest of Asia-Pacific

5.4.4 Middle East and Africa

5.4.4.1 GCC

5.4.4.2 South Africa

5.4.4.3 Rest of Middle East and Africa

5.4.5 South America

5.4.5.1 Brazil

5.4.5.2 Argentina

5.4.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)

6.3.1 Adaptimmune Therapeutics plc

6.3.2 AstraZeneca plc

6.3.3 Bayer AG

6.3.4 Bristol Myers Squibb Company

6.3.5 Daiichi Sankyo Company, Limited

6.3.6 Eisai Co., Ltd.

6.3.7 Eli Lilly and Company

6.3.8 F. Hoffmann-La Roche Ltd.

6.3.9 GSK plc

6.3.10 Illumina, Inc.

6.3.11 Merck & Co., Inc.

6.3.12 Nanobiotix S.A.

6.3.13 Novartis AG

6.3.14 Pfizer Inc.

6.3.15 QIAGEN N.V.

6.3.16 Sanofi

6.3.17 Sun Pharmaceutical Industries Ltd.

6.3.18 Teva Pharmaceutical Industries Ltd.

6.3.19 Thermo Fisher Scientific Inc.

6.3.20 Viatris Inc.

7 Market Opportunities and Future Outlook

7.1 White-Space and Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/tcuhtn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.